SEC Company Response from KIORA PHARMACEUTICALS INC (KPRX) (CIK 0001372514) (KPRX) — Jul 24, 2015
KIORA PHARMACEUTICALS INC (KPRX) (CIK 0001372514)
Date: July 24, 2015 · CIK: 0001372514 · Accession: 0001144204-15-044092
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-204780
Letter
AEGIS CAPITAL CORP.
810 Seventh Avenue
18th Floor
New York, NY 10019
July 24, 2015
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Eyegate Pharmaceuticals, Inc.
Registration Statement on Form S-1, as amended (File No. 333-204780)
Ladies and Gentlemen:
In accordance with the above-referenced Registration Statement, and pursuant to Rule 461 of the General Rules and Regulations of the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned, as the representative of the several underwriters (the “Representative”), hereby join in the request of Eyegate Pharmaceuticals, Inc. that the effective date of the above-referenced Registration Statement be accelerated so that it will be declared effective at 5:00 p.m., Eastern Time, on Tuesday, July 28, 2015, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Securities Act, please be advised that there will be distributed to each underwriter or dealer, who is reasonably anticipated to be invited to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
The undersigned, as the representative of the several underwriters, represent that the several underwriters have and will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[Signature page to follow]
Very truly yours,
AEGIS CAPITAL CORP.
Show Raw Text
CORRESP
1
filename1.htm
AEGIS CAPITAL CORP.
810 Seventh Avenue
18th Floor
New York, NY 10019
July 24, 2015
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Eyegate Pharmaceuticals, Inc.
Registration Statement on Form S-1, as amended
(File No. 333-204780)
Ladies and Gentlemen:
In accordance with
the above-referenced Registration Statement, and pursuant to Rule 461 of the General Rules and Regulations of the Securities and
Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned, as the representative
of the several underwriters (the “Representative”), hereby join in the request of Eyegate Pharmaceuticals, Inc. that
the effective date of the above-referenced Registration Statement be accelerated so that it will be declared effective at 5:00
p.m., Eastern Time, on Tuesday, July 28, 2015, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Securities
Act, please be advised that there will be distributed to each underwriter or dealer, who is reasonably anticipated to be invited
to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to
be reasonable to secure adequate distribution of the preliminary prospectus.
The undersigned, as the representative
of the several underwriters, represent that the several underwriters have and will comply with the requirements of Rule 15c2-8
under the Securities Exchange Act of 1934, as amended.
[Signature page to follow]
Very truly yours,
AEGIS CAPITAL CORP.
As Representative of the several underwriters named in
Schedule I to the Underwriting Agreement
By: AEGIS CAPITAL CORP.
By:
/s/ David S. Hentschel
Name: David S. Hentschel
Title: Compliance Officer